Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Oct

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer

Association of Survival With Treatment Recommendation and Receipt in Older Patients With Early-Stage Cervical Cancer

Patient-Reported Outcomes and Overall Survival in Cancer

Dose-Intensified Proton Therapy for Newly Diagnosed Glioblastoma

911 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers